Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
HF1K16 (ATRA liposome) is a novel small molecule RARβ2 agonist which is being evaluated in phase 1 clinical trials for the treatment of variety of refractory metastatic solid tumors such as gliomas and stomach, colorectal, liver, lung and ovarian cancers.
Lead Product(s): Tretinoin
Therapeutic Area: Oncology Product Name: HF1K16
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2024
Details:
HFK1 (HF158K1) is a drug encapsulated immunoliposome containing doxorubicin which is under phase 1 clinical development for the treatment of solid tumors.
Lead Product(s): HF158K1
Therapeutic Area: Oncology Product Name: HFK1
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2023
Details:
HF1K16 is a unique liposome construct of ATRA, a small molecule metabolite of vitamin A. It is administered by infusion, travels through the blood stream and infiltrates the tumor microenvironment.
Lead Product(s): Tretinoin
Therapeutic Area: Oncology Product Name: HF1K16
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 23, 2023
Details:
HF1K16 is a unique liposome construct of ATRA, a small molecule metabolite of vitamin A, administered by infusion, it travels through the blood stream and infiltrates the tumor microenvironment. ATRA is released and initiate maturation of myeloid-derived suppressor cell.
Lead Product(s): Tretinoin
Therapeutic Area: Oncology Product Name: HF1K16
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 17, 2023
Details:
HF158K1, a drug encapsulated immunoliposome containing doxorubicin, which being investigated forbsolid tumors include breast, bladder, pancreatic, ovarian, stomach, colon, prostate, lung, uterus and cervix cancers with HER2 low and HER2+ expression.
Lead Product(s): Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: HF158K1
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 13, 2023
Details:
HF1K16 is a unique liposome construct of ATRA, a small molecule metabolite of vitamin A, administered by infusion, which targets myeloid-derived suppressor cells (MDSCs) in patients with refractory glioblastoma.
Lead Product(s): Tretinoin
Therapeutic Area: Oncology Product Name: HF1K16
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2023